65360-27-2

Usage

Uses

Used in Peptide and Protein Synthesis:
N2,N6-Bis-Boc-D-lysine is used as a building block in the synthesis of peptides and proteins. The Boc protection groups enable selective deprotection, allowing for the stepwise assembly of complex peptide structures.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, N2,N6-Bis-Boc-D-lysine is utilized for the production of peptide-based therapeutics. Its Boc-protected nature allows for the synthesis of bioactive peptides with specific pharmacological properties.
Used in Pharmaceutical Development:
N2,N6-Bis-Boc-D-lysine is employed in the development of drug delivery systems. N2,N6-Bis-Boc-D-lysine can be incorporated into peptide-based drug carriers, enabling targeted delivery and controlled release of therapeutic agents.
Used in Materials Science:
N2,N6-Bis-Boc-D-lysine also finds applications in materials science, where it can be used to create biocompatible materials and surfaces with specific biological properties.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 70-53-1 2,6-diaminohexanoic acid hydrochloride 
• 70-54-2 2,6-diaminocaproic acid 

Downstream Products

• 125740-08-1 3-Amino-8-(2,6-bis-tert-butoxycarbonylamino-hexanoylamino)-5-ethyl-6-phenyl-phenanthridinium; bromide 
• 125740-07-0 3,8-Bis-(2,6-bis-tert-butoxycarbonylamino-hexanoylamino)-5-ethyl-6-phenyl-phenanthridinium; bromide 

Relevant academic research and scientific papers

Synthesis method for positive charge phospholipid

The invention relates to a synthesis method for positive charge phospholipid. 1,2-Palmitodistearin is adopted as a raw material, and phospholipid DSPE is synthesized; then, lysine is connected to an amino of the DSPE; then, n beta-alanines are connected to two aminos of a BOC-lysine group in the product, finally, a salt is obtained, and a series of positive charge phospholipid is obtained.

Synthesis and characterization of ramose tetralactosyllysyl-chitosan-5- fluorouracil and its in vitro release

In order to improve drug loading and achieve a good release effect, this paper adopts the ramose method, choosing chitosan as the carrier and 5-fluorouracil (5-Fu) as a model drug. Ramose chitosan-lysyl-5-Fu(3) and ramose tetralactosyllysyl- chitosan-5-Fu(6) were synthesized successfully, then the in vitro release of (6) was researched. The results show that the drug loading of (3) and (6) are 9.17 and 1.63% (w/w), respectively. The in vitro release behavior of (6) in pH 7.4 phosphate buffer solution and pH 1.2 HCl-KCl solution were studied. The zero order release time that (6) maintains in alkaline and acidic media are 64 and 24 h, and the total release by 184 h are 71.97 and 82.34%, respectively. The performance is smooth throughout the whole stage of release, and the concentration of cumulative release is lower in the alkaline environment than in the acidic environment over the same time. Springer Science+Business Media B.V. 2012.

1,3-Diarylprop-2-en-1-ones, compositions containing them and use thereof

1,3-Diarylprop-2-en-1-ones and derivatives, compositions containing them, manufacturing process and use. Substituted 1,3-diarylprop-2-en-1-ones with therapeutic activity may be used in oncology.

SYNTHESIS OF POLY(ETHYLENE GLYCOL) BLOCK COPOLYMERS AS POTENTIAL WATER-SOLUBLE DRUG CARRIERS

The synthesis of a model water-soluble drug carrier based on poly(ethylene glycol) (PEG) block copolymers is described.In the copolymers, two blocks of PEG are linked by a biodegradable oligopeptide or amino acid linkage containing the glutamic acid residue. 4-Nitroaniline as a drug model is attached to the γ-carboxyl group of glutamic acid of the polymer carrier via an enzymatically degradable oligopeptide spacer.The oligopeptides used were potential substrates for chymotrypsin.The relationship between the structure of oligopeptides linking two PEG blocks and the rate of chymotrypsin-catalyzed polymer chain degradation as well as the relationship between the structure of the spacer and kinetics of drug model release from the carrier after incubation of chymotrypsin solution is discussed in detail.The results showed that by modifying the structure of oligopeptides in the polymer construct, changes in the rates of both polymer degradation and the drug model release can be achieved in a very broad range.